Sean Konrad McHugh

Title: Innovations of Sean Konrad McHugh

Introduction

Sean Konrad McHugh is an accomplished inventor based in Ingleside, IL (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target Heat Shock Protein 90 (HSP90). With a total of 2 patents, McHugh's work is paving the way for new therapeutic options.

Latest Patents

One of McHugh's latest patents is focused on HSP90-inhibiting zearalanol compounds and methods of producing and using them. These zearalanol compounds are described as having potential utility in the treatment and prevention of various disorders. The patent outlines methods of synthesis and application for these compounds. Another notable patent involves ansamycins with improved pharmacological and biological properties. This patent details the preparation and use of ansamycins that exhibit enhanced aqueous formulation ability, chemical stability, and bioavailability. Some derivatives mentioned in this patent are dimers, which include solubilizing groups that enhance their effectiveness as drugs and prodrugs.

Career Highlights

Sean Konrad McHugh is currently associated with Conforma Therapeutics Corporation, where he continues to innovate in the pharmaceutical sector. His work is characterized by a commitment to developing compounds that can significantly impact medical treatments.

Collaborations

Throughout his career, McHugh has collaborated with notable professionals in the field, including Jean-Yves Le Brazidec and Marcus F Boehm. These collaborations have contributed to the advancement of his research and the successful development of his patents.

Conclusion

Sean Konrad McHugh's contributions to the field of pharmaceuticals through his innovative patents demonstrate his dedication to improving medical treatments. His work with HSP90-inhibiting compounds and ansamycins highlights the potential for significant advancements in therapeutic options.